Literature DB >> 3037735

Mucosal leishmaniasis ("espundia" Escomel, 1911).

P D Marsden.   

Abstract

One of the more serious clinical forms of leishmaniasis occurs in espundia when the mucosae of the upper respiratory passages are inflamed. This complication is a metastasis from a skin lesion caused by Leishmania braziliensis braziliensis (Lbb) although cases have been described associated with other leishmanial species. Epidemiological data suggest that a detectable mucosal metastasis occurs in fewer than 5% of patients infected with Lbb in our study area. The determinants of this complication are still largely obscure. The granuloma usually commences on the nasal septum. In about two-thirds of our patients the lesion remained restricted to the nose. In the rest the pharynx, palate, larynx and lips were involved, in this order. It is often difficult to isolate the parasite and for routine diagnosis the leishmanin skin reaction and serological tests are helpful. Although a serious condition, with possible mutilation and even death as subsequent complications, treatment is still mainly with pentavalent antimonials, introduced 40 years ago. These are most unsatisfactory for field use, being given parenterally and relatively toxic. In mucosal leishmaniasis, if sufficient antimony can be administered in a regular daily dose, the relapse rate is small (3 of 42 patients followed for a mean of 5 years). Also, antimony treatment of the initial skin ulcer due to Lbb followed for a mean of 4 years of 83 patients resulted in subsequent mucosal metastasis in only 2. Since espundia is relatively rare, specific treatment targeted to this specific problem is the efficient short term solution. At present there is no satisfactory alternative drug to those in current use.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3037735     DOI: 10.1016/0035-9203(86)90243-9

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  82 in total

1.  FLI1 polymorphism affects susceptibility to cutaneous leishmaniasis in Brazil.

Authors:  L Castellucci; S E Jamieson; E N Miller; L F de Almeida; J Oliveira; A Magalhães; L H Guimarães; M Lessa; E Lago; A R de Jesus; E M Carvalho; J M Blackwell
Journal:  Genes Immun       Date:  2011-06-02       Impact factor: 2.676

2.  A cluster of cutaneous leishmaniasis associated with human smuggling.

Authors:  Anthony P Cannella; Bichchau M Nguyen; Caroline D Piggott; Robert A Lee; Joseph M Vinetz; Sanjay R Mehta
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

Review 3.  Laboratory diagnosis of visceral leishmaniasis.

Authors:  Shyam Sundar; M Rai
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

4.  Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by Leishmania braziliensis.

Authors:  Tatiana R de Moura; Fernanda O Novais; Fabiano Oliveira; Jorge Clarêncio; Almério Noronha; Aldina Barral; Claudia Brodskyn; Camila I de Oliveira
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

5.  Role of Toll-like receptor 9 signaling in experimental Leishmania braziliensis infection.

Authors:  Tiffany Weinkopff; Anita Mariotto; Gregoire Simon; Yazmin Hauyon-La Torre; Floriane Auderset; Steffen Schuster; Haroun Zangger; Nicolas Fasel; Aldina Barral; Fabienne Tacchini-Cottier
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

6.  Multiclonal Leishmania braziliensis population structure and its clinical implication in a region of endemicity for American tegumentary leishmaniasis.

Authors:  A Schriefer; A L F Schriefer; A Góes-Neto; L H Guimarães; L P Carvalho; R P Almeida; P R Machado; H A Lessa; A Ribeiro de Jesus; L W Riley; E M Carvalho
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Functional variations in MBL2 gene are associated with cutaneous leishmaniasis in the Amazonas state of Brazil.

Authors:  F J de Araujo; T G Mesquita; L D O da Silva; S A de Almeida; W de S Vital; A Chrusciak-Talhari; J A de O Guerra; S Talhari; R Ramasawmy
Journal:  Genes Immun       Date:  2015-03-12       Impact factor: 2.676

Review 8.  Molecular epidemiology for vector research on leishmaniasis.

Authors:  Hirotomo Kato; Eduardo A Gomez; Abraham G Cáceres; Hiroshi Uezato; Tatsuyuki Mimori; Yoshihisa Hashiguchi
Journal:  Int J Environ Res Public Health       Date:  2010-03-05       Impact factor: 3.390

Review 9.  Drought, smallpox, and emergence of Leishmania braziliensis in northeastern Brazil.

Authors:  Anastácio Q Sousa; Richard Pearson
Journal:  Emerg Infect Dis       Date:  2009-06       Impact factor: 6.883

10.  First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony.

Authors:  Cesar Miranda-Verastegui; Gianfranco Tulliano; Theresa W Gyorkos; Wessmark Calderon; Elham Rahme; Brian Ward; Maria Cruz; Alejandro Llanos-Cuentas; Greg Matlashewski
Journal:  PLoS Negl Trop Dis       Date:  2009-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.